These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 21501631)

  • 1. Synergistic in vitro anti-HIV type 1 activity of tenofovir with carbohydrate-binding agents (CBAs).
    Férir G; Vermeire K; Huskens D; Balzarini J; Van Damme EJ; Kehr JC; Dittmann E; Swanson MD; Markovitz DM; Schols D
    Antiviral Res; 2011 Jun; 90(3):200-4. PubMed ID: 21501631
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro evaluation of the anti-HIV activity and metabolic interactions of tenofovir and emtricitabine.
    Borroto-Esoda K; Vela JE; Myrick F; Ray AS; Miller MD
    Antivir Ther; 2006; 11(3):377-84. PubMed ID: 16759055
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiviral efficacy and genotypic resistance patterns of combination therapy with stavudine/tenofovir in highly active antiretroviral therapy experienced patients.
    Antinori A; Trotta MP; Nasta P; Bini T; Bonora S; Castagna A; Zaccarelli M; Quirino T; Landonio S; Merli S; Tozzi V; Di Perri G; Andreoni M; Perno CF; Carosi G
    Antivir Ther; 2006; 11(2):233-43. PubMed ID: 16640104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increasing prevalence of HIV-1 reverse transcriptase mutation K65R correlates with tenofovir utilization.
    Kagan RM; Merigan TC; Winters MA; Heseltine PN
    Antivir Ther; 2004 Oct; 9(5):827-8. PubMed ID: 15535422
    [No Abstract]   [Full Text] [Related]  

  • 5. Combination of antiretroviral drugs as microbicides.
    Balzarini J; Schols D
    Curr HIV Res; 2012 Jan; 10(1):53-60. PubMed ID: 22264046
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergy against drug-resistant HIV-1 with the microbicide antiretrovirals, dapivirine and tenofovir, in combination.
    Schader SM; Colby-Germinario SP; Schachter JR; Xu H; Wainberg MA
    AIDS; 2011 Aug; 25(13):1585-94. PubMed ID: 21633286
    [TBL] [Abstract][Full Text] [Related]  

  • 7. K65R development among subtype C HIV-1-infected patients in tenofovir DF clinical trials.
    Miller MD; Margot N; McColl D; Cheng AK
    AIDS; 2007 Jan; 21(2):265-6. PubMed ID: 17197831
    [No Abstract]   [Full Text] [Related]  

  • 8. Combinations of griffithsin with other carbohydrate-binding agents demonstrate superior activity against HIV Type 1, HIV Type 2, and selected carbohydrate-binding agent-resistant HIV Type 1 strains.
    Férir G; Huskens D; Palmer KE; Boudreaux DM; Swanson MD; Markovitz DM; Balzarini J; Schols D
    AIDS Res Hum Retroviruses; 2012 Nov; 28(11):1513-23. PubMed ID: 22607556
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of tenofovir subtraction on HIV plasma viraemia, CD4+ T-cell count and resistance in a patient with baseline K65R and M184V mutations.
    Hsu R; Lanier ER; Rouse EG; Oie KL; Pappa KA; Ross LL
    Antivir Ther; 2008; 13(5):735-7. PubMed ID: 18771059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of tenofovir double-dose in treatment-experienced HIV-infected patients: the TENOPLUS study.
    Dominguez S; Ghosn J; Peytavin G; Izzedine H; Wirden M; Ktorza N; Miller M; Aubron-Olivier C; Trylesinski A; Calvez V; Deray G; Katlama C
    J Med Virol; 2007 Feb; 79(2):105-10. PubMed ID: 17177308
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiretroviral efficacy and virological profile of a zidovudine/lamivudine/tenofovir disoproxil fumarate combination therapy in antiretroviral-naive patients.
    Masquelier B; Neau D; Boucher S; Lavignolle-Aurillac V; Schrive MH; Recordon-Pinson P; Ragnaud JM; Fleury H
    Antivir Ther; 2006; 11(6):827-30. PubMed ID: 17310827
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tenofovir disoproxil fumarate.
    Gallant JE; Deresinski S
    Clin Infect Dis; 2003 Oct; 37(7):944-50. PubMed ID: 13130407
    [TBL] [Abstract][Full Text] [Related]  

  • 13. K65R, TAMs and tenofovir.
    Miller MD
    AIDS Rev; 2004; 6(1):22-33. PubMed ID: 15168738
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changing patterns in HIV reverse transcriptase resistance mutations after availability of tenofovir.
    de Mendoza C; Jiménez-Nacher I; Garrido C; Barreiro P; Poveda E; Corral A; Zahonero N; González-Lahoz J; Soriano V
    Clin Infect Dis; 2008 Jun; 46(11):1782-5. PubMed ID: 18426370
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro analysis of synergism and antagonism of different nucleoside/nucleotide analogue combinations on the inhibition of human immunodeficiency virus type 1 replication.
    Perez-Olmeda M; Garcia-Perez J; Mateos E; Spijkers S; Ayerbe MC; Carcas A; Alcami J
    J Med Virol; 2009 Feb; 81(2):211-6. PubMed ID: 19107982
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Carbohydrate-binding agents (CBAs) inhibit HIV-1 infection in human primary monocyte-derived macrophages (MDMs) and efficiently prevent MDM-directed viral capture and subsequent transmission to CD4+ T lymphocytes.
    Pollicita M; Schols D; Aquaro S; Peumans WJ; Van Damme EJ; Perno CF; Balzarini J
    Virology; 2008 Jan; 370(2):382-91. PubMed ID: 17928023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of saquinavir hard gel/ritonavir (1000/100 mg twice daily) when administered with tenofovir diproxil fumarate in HIV-1-infected subjects.
    Boffito M; Back D; Stainsby-Tron M; Hill A; Di Perri G; Moyle G; Nelson M; Tomkins J; Gazzard B; Pozniak A
    Br J Clin Pharmacol; 2005 Jan; 59(1):38-42. PubMed ID: 15606438
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipid-lowering effect of tenofovir in HIV-infected patients.
    Fabbiani M; Bracciale L; Doino M; Sidella L; Farina S; Di Cristo V; Cauda R; De Luca A; Di Giambenedetto S
    J Antimicrob Chemother; 2011 Mar; 66(3):682-3. PubMed ID: 21131692
    [No Abstract]   [Full Text] [Related]  

  • 19. Inhibition of HIV-1 entry: multiple keys to close the door.
    Hertje M; Zhou M; Dietrich U
    ChemMedChem; 2010 Nov; 5(11):1825-35. PubMed ID: 20845361
    [No Abstract]   [Full Text] [Related]  

  • 20. Effect of tenofovir on didanosine absorption in patients with HIV.
    Pecora Fulco P; Kirian MA
    Ann Pharmacother; 2003 Sep; 37(9):1325-8. PubMed ID: 12921517
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.